← All trials
NCT06856577
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2025
- Primary completion
- Dec 22, 2026
- Completion date
- Nov 23, 2030
- First posted
- Mar 4, 2025
- Last posted
- Nov 18, 2025
- Enrollment
- 284
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Adverum Biotechnologies, Inc.Lead sponsor
- Adverum Biotechnologies, Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.